HAVCR2 and neoplasm: We assessed its co-expression with TIGIT, Tim-3, LAG-3, BTLA, and NKG2A across four groups: treatment-naïve CC patients and total CC patients (Figure 4a), and peripheral CD8+ T cells from peripheral treatment-naive PBMCs versus tumor-infiltrating CD8+ T cells from biopsies of treatment-naive tumors (Figure 4b).